The Asia-Pacific Lung Cancer Therapeutics Market was worth $0.96 billion in 2016 and estimated to be growing at a CAGR of 7.65%, to reach $1.39 billion by 2021. Asia-Pacific countries such as India and China are the developing regions for the global lung cancer therapeutics market owing to high occurrence of this disease along with growing healthcare alertness.
Lung cancer accounts for a greater share of the whole number of patients suffering with cancer. Small cell lung cancer type is dangerous due to the fact that there are no drugs present for its treatment and that the smaller size of cancer cells present in this type of cancer make it harder to be treated even by surgical involvement.
Browse market data tables and in-depth TOC of the Asia-Pacific Lung Cancer Therapeutics Market to 2021 @ http://www.marketdataforecast.com/market-reports/asia-pacific-lung-cancer-therapeutics-market-896/
Lung cancer therapeutics market is expected to observe profitable growth in the coming years largely due to the stable increase in the occurrence of cancer cases. As the geriatric population is likely to increase, the incidence of lung cancer is predicted to rise, thus acting as a driver for revenue growth. Lack of awareness among patients and side effects associated with the treatment therapies are expected to obstruct the growth of lung cancer therapeutics market.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/asia-pacific-lung-cancer-therapeutics-market-896/request-sample
The Asia-Pacific Lung Cancer Therapeutics Market is segmented on the basis of treatment type nto Chemotherapy, Radiotherapy and Other Drugs. Based on drug type, Lung Cancer Chemotherapy market is segmented into cisplatin, taxol, navelbine, camptosar and Alimta. Based on type, Lung Cancer Radiotherapy market is segregated into external beam, internal beam and systemic. On the basis of drug type, Other Lung Cancer Therapeutic Drugs market is segmented into abraxane, avastin, crizotinib, docetaxel and Gefitinib. The top global brands that are commercially accessible in the market are Avastin, Alimta and taxol. Radiotherapy accounts for the largest segment in the lung cancer therapeutics market.
Based on geography the market is analysed under various regions namely, China, India, Japan, South Korea and Australia. Increasing population base in the countries like India and China is anticipated to increase the growth of this market in these areas.
Companies are implementing various strategies to increase their product portfolio and rise its geographical presence. New product expansion, contracts and associations and procurements are some of the significant approaches adopted by the manufacturers in the lung cancer therapeutics market. The prominent players of this market include BoehringerIngelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmitKline, Eli Lilly and Company, Agennix AG, AstrazenecaPlc, and Sanofi-Aventis.
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions.
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: [email protected]
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases